These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
500 related articles for article (PubMed ID: 1688087)
41. Lack of in vivo effect of granulocyte-macrophage colony-stimulating factor on human immunodeficiency virus type 1. Scadden DT; Pickus O; Hammer SM; Stretcher B; Bresnahan J; Gere J; McGrath J; Agosti JM AIDS Res Hum Retroviruses; 1996 Aug; 12(12):1151-9. PubMed ID: 8844019 [TBL] [Abstract][Full Text] [Related]
42. Acute reactions associated with the infusion of ampligen. McMahon D; Winkelstein A; Huang XL; Armstrong J; Pazin G; Rinaldo C; Tripoli C; Ho M AIDS; 1992 Feb; 6(2):235-6. PubMed ID: 1558725 [No Abstract] [Full Text] [Related]
43. Quantification of HIV-1 virus load under zidovudine therapy in patients with symptomatic HIV infection: relation to disease progression. Molina JM; Ferchal F; Chevret S; Barateau V; Poirot C; Morinet F; Modai J AIDS; 1994 Jan; 8(1):27-33. PubMed ID: 7912084 [TBL] [Abstract][Full Text] [Related]
44. Synthesis and evaluation of a novel synthetic phosphocholine lipid-AZT conjugate that double-targets wild-type and drug resistant variants of HIV. Kucera LS; Morris-Natschke SL; Ishaq KS; Hes J; Iyer N; Furman PA; Fleming RA Nucleosides Nucleotides Nucleic Acids; 2004; 23(1-2):385-99. PubMed ID: 15043162 [TBL] [Abstract][Full Text] [Related]
45. PolyI.polyC12U-mediated inhibition of loss of alloantigen responsiveness viral replication in human CD4+ T cell clones exposed to human immunodeficiency virus in vitro. Laurence J; Kulkosky J; Friedman SM; Posnett DN; Ts'o PO J Clin Invest; 1987 Dec; 80(6):1631-9. PubMed ID: 2960696 [TBL] [Abstract][Full Text] [Related]
46. Combined antiviral therapy reduces HIV-1 plasma load and improves CD4 counts but does not interfere with ongoing lymphocyte apoptosis. Moretti S; Alesse E; Marcellini S; Di Marzio L; Zazzeroni F; Parroni R; Famularo G; Boschini A; Cifone MG; De Simone C Immunopharmacol Immunotoxicol; 1999 Nov; 21(4):645-65. PubMed ID: 10584202 [TBL] [Abstract][Full Text] [Related]
47. Anti-retroviral therapy in HIV-infected patients: in vitro effects of AZT and saquinavir on the response of CD4 and CD8 lymphocytes to interleukin-7. Beq S; Bugault F; Colle JH; Lambotte O; Delfraissy JF; Thèze J Eur Cytokine Netw; 2005 Dec; 16(4):293-9. PubMed ID: 16464744 [TBL] [Abstract][Full Text] [Related]
48. Susceptibility to nucleoside analogues of zidovudine-resistant isolates of human immunodeficiency virus. Richman DD Am J Med; 1990 May; 88(5B):8S-10S. PubMed ID: 2186629 [TBL] [Abstract][Full Text] [Related]
49. Development of zidovudine (AZT) resistance in Jurkat T cells is associated with decreased expression of the thymidine kinase (TK) gene and hypermethylation of the 5' end of human TK gene. Wu S; Liu X; Solorzano MM; Kwock R; Avramis VI J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jan; 8(1):1-9. PubMed ID: 8548339 [TBL] [Abstract][Full Text] [Related]
51. 3TC/AZT: just another combination. GMHC Treat Issues; 1995 Dec; 9(12):2. PubMed ID: 11362997 [TBL] [Abstract][Full Text] [Related]
52. Sulfated polysaccharides extracted from sea algae as potential antiviral drugs. Witvrouw M; De Clercq E Gen Pharmacol; 1997 Oct; 29(4):497-511. PubMed ID: 9352294 [TBL] [Abstract][Full Text] [Related]
53. Drug combinations and effect parameters of zidovudine, stavudine, and nevirapine in standardized drug-sensitive and resistant HIV type 1 strains. Zhu QY; Scarborough A; Polsky B; Chou TC AIDS Res Hum Retroviruses; 1996 Apr; 12(6):507-17. PubMed ID: 8679306 [TBL] [Abstract][Full Text] [Related]
54. Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017). Mulder JW; Cooper DA; Mathiesen L; Sandström E; Clumeck N; Gatell JM; French M; Donovan B; Gray F; Yeo JM AIDS; 1994 Mar; 8(3):313-21. PubMed ID: 7913326 [TBL] [Abstract][Full Text] [Related]
55. Inhibition of entry of HIV into cells by poly(A).poly(U). Krust B; Callebaut C; Hovanessian AG AIDS Res Hum Retroviruses; 1993 Nov; 9(11):1087-90. PubMed ID: 8312051 [TBL] [Abstract][Full Text] [Related]
56. Therapeutic potential of Ampligen. Brodsky I; Strayer DR Am Fam Physician; 1987 Oct; 36(4):253-6. PubMed ID: 3673869 [No Abstract] [Full Text] [Related]
57. A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome. Strayer DR; Carter WA; Brodsky I; Cheney P; Peterson D; Salvato P; Thompson C; Loveless M; Shapiro DE; Elsasser W Clin Infect Dis; 1994 Jan; 18 Suppl 1():S88-95. PubMed ID: 8148460 [TBL] [Abstract][Full Text] [Related]
58. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. Staszewski S; Loveday C; Picazo JJ; Dellarnonica P; Skinhøj P; Johnson MA; Danner SA; Harrigan PR; Hill AM; Verity L; McDade H JAMA; 1996 Jul; 276(2):111-7. PubMed ID: 8656502 [TBL] [Abstract][Full Text] [Related]
59. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. Katlama C; Ingrand D; Loveday C; Clumeck N; Mallolas J; Staszewski S; Johnson M; Hill AM; Pearce G; McDade H JAMA; 1996 Jul; 276(2):118-25. PubMed ID: 8656503 [TBL] [Abstract][Full Text] [Related]
60. Synergistic antiviral effect in vitro of azidothymidine and amphotericin B methyl ester in combination on HIV infection. Hansen JE; Nielsen C; Svenningsen A; Witzke N; Mathiesen LR Scand J Infect Dis; 1992; 24(1):35-9. PubMed ID: 1589723 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]